SMITHKLINE BEECHAM COREG NEEDS CONFIRMATORY STUDY FOR CHF INDICATION; MORTALITY BENEFIT NOT STATISTICALLY SHOWN IN TRIALS, ADVISORY COMMITTEE FINDS
Executive Summary
SmithKline Beecham's Coreg would require a confirmatory study for clearance as a treatment for congestive heart failure, FDA's Cardiovascular & Renal Drugs Advisory Committee concluded at its May 2 meeting.